San Diego-based Optimer Pharmaceuticals said today that it is offering 7,000,000 shares of its common stock at a price of $7.00 per share in its IPO. Optimer is listing its stock on the NASDAQ Global Market under the symbol "OPTR", in an IPO underwritten by Piper Jaffray & Co., Jefferies & Company, JMP Securities, and Rodman & Renshaw. Optimer is developing biopharmaceuticals for the treatment of serious infections, and is backed by BB Biotech Ventures, CDIB Ventures, ESun Bank Group, Fubon Financial Holding Venture, Global Strategic Investments, Lurie Investments, Oriental Union Chemical Corp., Par Pharmaceutical Companies, Proquest Investments, SB Life Science Ventures, Taiwan Global BioFund, and UOB JAIC Venture Bio Investments.
Top NewsFriday, February 9, 2007
Optimer Pharmaceuticals Prices IPO